248 related articles for article (PubMed ID: 22535374)
21. Forskolin increases neuregulin receptors in human Schwann cells without increasing receptor mRNA.
Fregien NL; White LA; Bunge MB; Wood PM
Glia; 2005 Jan; 49(1):24-35. PubMed ID: 15390106
[TBL] [Abstract][Full Text] [Related]
22. Dual-targeting therapy against HER3/MET in human colorectal cancers.
Yamasaki A; Miyake R; Hara Y; Okuno H; Imaida T; Okita K; Okazaki S; Akiyama Y; Hirotani K; Endo Y; Masuko K; Masuko T; Tomioka Y
Cancer Med; 2023 Apr; 12(8):9684-9696. PubMed ID: 36751113
[TBL] [Abstract][Full Text] [Related]
23. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
24. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
25. An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Liu Y; Zheng P; Liu Y; Ji T; Liu X; Yao S; Cheng X; Li Y; Chen L; Xiao Z; Zhou J; Li J
Gut; 2013 Apr; 62(4):571-81. PubMed ID: 22345654
[TBL] [Abstract][Full Text] [Related]
26. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
[TBL] [Abstract][Full Text] [Related]
27. HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome.
Lédel F; Hallström M; Ragnhammar P; Öhrling K; Edler D
Eur J Cancer; 2014 Feb; 50(3):656-62. PubMed ID: 24300455
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
29. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
30. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
31. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.
Yamanashi T; Nakanishi Y; Fujii G; Akishima-Fukasawa Y; Moriya Y; Kanai Y; Watanabe M; Hirohashi S
Oncology; 2009; 77(1):53-62. PubMed ID: 19556810
[TBL] [Abstract][Full Text] [Related]
32. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
[TBL] [Abstract][Full Text] [Related]
33. Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β1-integrin-dependent mechanism.
Widder M; Lützkendorf J; Caysa H; Unverzagt S; Wickenhauser C; Benndorf RA; Schmoll HJ; Müller-Tidow C; Müller T; Müller LP
Int J Cancer; 2016 Feb; 138(4):964-75. PubMed ID: 26356035
[TBL] [Abstract][Full Text] [Related]
34. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation.
Stove C; Stove V; Derycke L; Van Marck V; Mareel M; Bracke M
J Invest Dermatol; 2003 Oct; 121(4):802-12. PubMed ID: 14632199
[TBL] [Abstract][Full Text] [Related]
35. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.
Frohnert PW; Stonecypher MS; Carroll SL
Glia; 2003 Aug; 43(2):104-18. PubMed ID: 12838503
[TBL] [Abstract][Full Text] [Related]
36. GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer.
Wu J; Xie N; Xie K; Zeng J; Cheng L; Lei Y; Liu Y; Song L; Dong D; Chen Y; Zeng R; Nice EC; Huang C; Wei Y
Carcinogenesis; 2013 Dec; 34(12):2861-9. PubMed ID: 23803691
[TBL] [Abstract][Full Text] [Related]
37. HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition.
Jia X; Wang H; Li Z; Yan J; Guo Y; Zhao W; Gao L; Wang B; Jia Y
Mol Med Rep; 2020 Apr; 21(4):1779-1788. PubMed ID: 32319604
[TBL] [Abstract][Full Text] [Related]
38. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer.
Yonezawa M; Wada K; Tatsuguchi A; Akamatsu T; Gudis K; Seo T; Mitsui K; Nagata K; Tanaka S; Fujimori S; Sakamoto C
Digestion; 2009; 80(4):215-25. PubMed ID: 19797898
[TBL] [Abstract][Full Text] [Related]
39. STAT5 isoforms regulate colorectal cancer cell apoptosis via reduction of mitochondrial membrane potential and generation of reactive oxygen species.
Du W; Wang YC; Hong J; Su WY; Lin YW; Lu R; Xiong H; Fang JY
J Cell Physiol; 2012 Jun; 227(6):2421-9. PubMed ID: 21826656
[TBL] [Abstract][Full Text] [Related]
40. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
